AMADIS
1.5.2022 07:02:07 CEST | Business Wire | Press release
Amadis , a leading payment software and consulting provider, today announced a partnership agreement with Softpay.io to provide its Universal EMV Level 2 Framework & pre-certified Kernels for integration into Softpay’s new Tap-to-Pay service. Softpay’s revolutionary Tap-to-Pay service can be downloaded into any Android device and turn into a full payment card acceptance terminal. Softpay’s solution provides merchants with greater flexibility and future proofing capabilities, while lowering costs and creating new revenue opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220430005009/en/
The Amadis solution is a component of its Amadis One software framework composed of an EMV L2 Framework and ecosystem supporting any EMV Contactless Kernel. It enables Softpay’s service to seamlessly accept EMV payments on Android-based COTS devices with NFC capabilities, reduces the time for Softpay to roll out new products and provide payment acceptance of any payment schemes, on its new mobile payments platform. Amadis One software framework is the first solution to enable nexo (ISO 202022) standards on Tap-to-Pay platforms.
“Softpay’s solution helps us to transform the shopping experience, enabling our store associates to check out customers anywhere in-store, or at curbside,” said Thomas Grane, CIO, at Matas. “The solution drives new sales opportunities, and enables a more efficient, personalized customer experience.”
Softpay’s Tap-to-Pay is impacting several industries, including retailers and QSRs, who can operate more efficiently. Staff can accept payments, while multi-tasking anywhere in-store, or at curbside pickup locations. Transit companies can drive new points of sale by instantly offering and processing new and upgraded tickets, while passengers are on board trains and buses.
“Softpay’s Tap-to-Pay service provides innovative new experiences to retail, transportation and the QSR industries, and our Amadis One software framework helps them bring products to market faster,” said Emmanuel Haydont, CEO and co-founder, Amadis. “Amadis One commoditizes complex payment processes, freeing up resources for merchants to innovate, accelerating time to market and reducing costs, while enhancing the customer experience.”
“By integrating Amadis One with our Tap-to-Pay solution, we enable merchants to revolutionize the customer experience, while lowering their costs and providing greater flexibility,” said Craig Jacoby, CEO, Softpay.io. “By enabling tap-to-pay transactions on smartphones, merchant fees for card present transactions are lowered, new customer points of interactions (POIs) are generated, creating innovative new ways to interact with customers, while processing transactions.”
About Softpay.io
Softpay was founded in 2019 to take advantage of the new Visa and Mastercard specifications for payment terminals which enabled Softpay to develop a mobile application that allows merchants to turn a regular phone into a contactless payment terminal with PIN. Softpay has grown into a company with more than 30 employees and is headquartered in Copenhagen, Denmark. Softpay has received more than €9 mill in funding and the ambition is to be one of the leading global providers of tap-to-phone solutions. Leading European payment companies have decided to partner with Softpay and Softpay is now focusing on North America as well.
About Amadis
Amadis is a leader in payment card acceptance software technology, with its software running on more than 50 million devices worldwide. The company provides state-of-the-art software products, frameworks and solutions for global merchants, payment terminal manufacturers and payment processors. Amadis provides merchants with the industry’s broadest range of EMV card processing options using custom or commercially available technology, independent of hardware, operating system or geography. The company brings an elite, experienced software team to the industry and enables solutions for international acceptors in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220430005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom